CARE study reports complete regression of liver cancer in a child treated with novel immunotherapy

A new report in the New England Journal of Medicine by researchers at Baylor College of Medicine, Texas Children’s Hospital and Seattle Children’s describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in a 3-year-old treated with a novel immunotherapy.

Read more: https://www.bcm.edu/news/care-study-reports-complete-regression-of-liver-cancer-in-a-child-treated-with-novel-immunotherapy